Show simple item record

dc.contributor.authorReljic, R
dc.contributor.authorClark, S O
dc.contributor.authorWilliams, A
dc.contributor.authorFalero-Diaz, G
dc.contributor.authorSingh, M
dc.contributor.authorChallacombe, S
dc.contributor.authorMarsh, P D
dc.contributor.authorIvanyi, J
dc.date.accessioned2007-11-15T09:34:37Z
dc.date.available2007-11-15T09:34:37Z
dc.date.issued2006-03-01
dc.identifier.citationClin. Exp. Immunol. 2006, 143(3):467-73en
dc.identifier.issn0009-9104
dc.identifier.pmid16487246
dc.identifier.doi10.1111/j.1365-2249.2006.03012.x
dc.identifier.urihttp://hdl.handle.net/10033/14575
dc.description.abstractIntranasal inoculation of mice with monoclonal IgA against the alpha-crystallin (acr1) antigen can diminish the tuberculous infection in the lungs. As this effect has been observed only over a short-term, we investigated if it could be extended by inoculation of IFNgamma 3 days before infection, and further co-inoculations with IgA, at 2 h before and 2 and 7 days after aerosol infection with Mycobacterium tuberculosis H37Rv. This treatment reduced the lung infection at 4 weeks more than either IgA or IFNgamma alone (i.e. 17-fold, from 4.2 x 10(7) to 2.5 x 10(6) CFU, P = 0.006), accompanied also by lower granulomatous infiltration of the lungs. IFNgamma added prior to infection of mouse peritoneal macrophages with IgA-opsonized bacilli resulted in a synergistic increase of nitric oxide and TNFalpha production and a 2-3 fold decrease in bacterial counts. Our improved results suggest, that combined treatment with IFNgamma and IgA could be developed towards prophylactic treatment of AIDS patients, or as an adjunct to chemotherapy.
dc.format.extent5847539 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoenen
dc.titleIntranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.en
dc.typeArticleen
dc.format.digYES
refterms.dateFOA2018-06-13T00:42:22Z
html.description.abstractIntranasal inoculation of mice with monoclonal IgA against the alpha-crystallin (acr1) antigen can diminish the tuberculous infection in the lungs. As this effect has been observed only over a short-term, we investigated if it could be extended by inoculation of IFNgamma 3 days before infection, and further co-inoculations with IgA, at 2 h before and 2 and 7 days after aerosol infection with Mycobacterium tuberculosis H37Rv. This treatment reduced the lung infection at 4 weeks more than either IgA or IFNgamma alone (i.e. 17-fold, from 4.2 x 10(7) to 2.5 x 10(6) CFU, P = 0.006), accompanied also by lower granulomatous infiltration of the lungs. IFNgamma added prior to infection of mouse peritoneal macrophages with IgA-opsonized bacilli resulted in a synergistic increase of nitric oxide and TNFalpha production and a 2-3 fold decrease in bacterial counts. Our improved results suggest, that combined treatment with IFNgamma and IgA could be developed towards prophylactic treatment of AIDS patients, or as an adjunct to chemotherapy.


Files in this item

Thumbnail
Name:
Reljic_final.pdf
Size:
5.576Mb
Format:
PDF
Description:
original document

This item appears in the following Collection(s)

Show simple item record